Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2009

01-06-2009 | Short Communication

Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report

Authors: Anubha Bharthuar, Lori Egloff, Joanne Becker, Marina George, James W. Lohr, George Deeb, Renuka V. Iyer

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2009

Login to get access

Abstract

Purpose

The purpose of this report is to describe the management and outcome of an unusual complication of a commonly used chemotherapeutic agent. Gemcitabine is a known risk factor for hemolytic uremic syndrome (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.

Methods

A retrospective report of the first case of gemcitabine-related HUS, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented. The hematologic response parameters and clinical outcomes to each of the therapies given are described.

Results

Chemotherapy-induced HUS was aggressively treated with plasmapheresis, high-dose steroids, vincristine and rituximab. Platelet recovery and clinical improvement coincided with administration of rituximab. In addition, aggressive supportive measures to manage renal failure (hemodialysis) and labile hypertension, allowed this patient to have an extended survival as a result of successful therapy for this complication despite an underlying rapidly fatal malignancy.

Conclusion

This case highlights the importance of timely application of aggressive measures even in patients with known diagnosis of a fatal malignancy as these interventions can prolong life and be of palliative benefit.
Literature
1.
Casper ES, Green MR, Kelsen DP et al (1994) Phase II trial of gemcitabine (2, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29–34PubMedCrossRef
2.
Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85:2023–2032PubMed
3.
Desrame J, Duvic C, Bredin C et al (2005) Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature. Rev Med Interne 26:179–188PubMedCrossRef
4.
Gross M, Hiesse C, Kriaa F, Goldwasser F (1999) Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Anticancer Drugs 10:533–536PubMedCrossRef
5.
Teixeira L, Debourdeau P, Zammit C, Estival JL, Pavic M, Colle B (2002) Gemcitabine-induced thrombotic microangiopathy. Presse Med 31:740–742PubMed
6.
Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC (1997) Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst 89:1895–1896PubMedCrossRef
7.
Lhotta K, Kuhr T, Rumpelt HJ, Woll E, Thaler J, Konig P (1999) Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol 19:590–593PubMedCrossRef
8.
Venat-Bouvet L, Ly K, Szelag JC et al (2003) Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine. Anticancer Drugs 14:829–832PubMedCrossRef
9.
Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127:834–839PubMed
10.
Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60:831–846PubMedCrossRef
11.
von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6:320–328CrossRef
12.
Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584PubMedCrossRef
13.
Yassa SK, Blessios G, Marinides G, Venuto RC (2005) Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transpl 19:423–426CrossRef
14.
Ostronoff M, Ostronoff F, Calixto R et al (2007) Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient. Bone Marrow Transplant 39:649–651PubMedCrossRef
15.
Fakhouri F, Teixeira L, Delarue R, Grunfeld JP, Veyradier A (2004) Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med 140:314–315PubMed
16.
Galbusera M, Bresin E, Noris M et al (2005) Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 106:925–928PubMedCrossRef
17.
Kaneko H, Matsumoto M, Okamoto K et al (2007) Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine. Rinsho Ketsueki 48:144–147PubMed
18.
Fakhouri F, Vernant JP, Veyradier A et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932–1937PubMedCrossRef
19.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
20.
Burris H, Storniolo AM (1997) Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 331 Suppl 1:S18–S22CrossRef
21.
Moake JL, Rudy CK, Troll JH et al (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435PubMed
22.
Snyder HW Jr, Mittelman A, Oral A et al (1993) Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 71:1882–1892PubMedCrossRef
23.
Bohm M, Betz C, Miesbach W et al (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 129:644–652PubMedCrossRef
24.
O’Connor NT, Bruce-Jones P, Hill LF (1992) Vincristine therapy for thrombotic thrombocytopenic purpura. Am J Hematol 39:234–236PubMedCrossRef
25.
Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed
Metadata
Title
Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report
Authors
Anubha Bharthuar
Lori Egloff
Joanne Becker
Marina George
James W. Lohr
George Deeb
Renuka V. Iyer
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0900-x

Other articles of this Issue 1/2009

Cancer Chemotherapy and Pharmacology 1/2009 Go to the issue

Original Article

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor

Erratum

Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form

Mini Review

Treatment of metastatic renal cell carcinoma

Original Article

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients

Mini Review

Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?

Original Article

Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits